Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone-Reference-Cited by-同舟云学术

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

Published:2018-09 Issue: Volume:12 Page:19-30
ISSN:2405-6502
Container-title:eNeurologicalSci
language:en
Short-container-title:eNeurologicalSci

Author:

Melamed-Gal S.,Loupe P.,Timan B.,Weinstein V.,Kolitz S.,Zhang J.,Funt J.,Komlosh A.,Ashkenazi N.,Bar-Ilan O.,Konya A.,Beriozkin O.,Laifenfeld D.,Hasson T.,Krispin R.,Molotsky T.,Papir G.,Sulimani L.,Zeskind B.,Liu P.,Nock S.,Hayden M.R.,Gilbert A.,Grossman I.

Publisher

Elsevier BV

Subject

Neurology

Reference34 articles.

1. Non-Biological Complex Drugs. The Science and the Regulatory Landscape;Weinstein,2015

2. Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate;Campos-García;J. Pharm. Biomed. Anal.,2017

3. Equivalence of Generic glatiramer Acetate in Multiple Sclerosis: a randomized clinical trial;Cohen;JAMA Neurol.,2015

4. Annovazzi P., Bertolott A., Morra V.B. et al., A comprehensive review on Copemyl. Neurol Ther. DOI 10.1007/540120-017-0079.3

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rock-to-Pharma: Characterization of Shale Oil-Based Nonbiological Complex Drugs along the Production Process by High-Resolution Mass Spectrometry;Analytical Chemistry;2024-07-31

2. Exploiting Pharma 4.0 Technologies in the Non-Biological Complex Drugs Manufacturing: Innovations and Implications;Pharmaceutics;2023-10-28

3. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products;Journal of Pharmaceutical Sciences;2022-10

4. Development of Pharmaceutical Nanomedicines: From the Bench to the Market;Pharmaceutics;2022-01-03

5. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany;Neurodegenerative Disease Management;2021-12-21